Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTS2R | Q9UKP6 | 20/20 | 0.94 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxalic Acid SCHEMBL5458489 | 0.83 | UTS2R (0.96) | UTS2R | |
| Oxalic Acid SCHEMBL5463495 | 0.82 | UTS2R (0.93) | UTS2R | |
| Oxalic Acid SCHEMBL5456003 | 0.80 | UTS2R (0.94) | UTS2R | |
| Oxalic Acid SCHEMBL5458608 | 0.80 | UTS2R (0.94) | UTS2R | |
| Oxalic Acid SCHEMBL5463944 | 0.80 | UTS2R (0.96) | UTS2R | |
| Oxalic Acid SCHEMBL5465548 | 0.80 | UTS2R (0.96) | UTS2R | |
| Oxalic Acid SCHEMBL5452751 | 0.80 | UTS2R (0.95) | UTS2R | |
| SCHEMBL14201577 | 0.80 | UTS2R (1.00) | UTS2R | |
| SCHEMBL20544776 | 0.80 | UTS2R (0.73) | UTS2R | |
| Oxalic Acid SCHEMBL5461105 | 0.78 | UTS2R (0.94) | UTS2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043104-A1 | UII-modulating compounds and their use | ACADIA PHARMACEUTICALS INC. | 2007-02-22 | — | — | US | claimed |
| WO-2006135694-A2 | UII-MODULATING COMPOUNDS AND THEIR USE | ACADIA PHARMACEUTICALS INC. (US) | 2006-12-21 | — | — | WO | claimed |
| US-20070043104-A1 | UII-modulating compounds and their use | ACADIA PHARMACEUTICALS INC. | 2007-02-22 | — | — | US | disclosed |
| WO-2006135694-A2 | UII-MODULATING COMPOUNDS AND THEIR USE | ACADIA PHARMACEUTICALS INC. (US) | 2006-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043104-A1 | UII-modulating compounds and their use | UTS2R, GPR17, GPR119 | UTS2R 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.